This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grunfeld, J. P. Articles by Worcel, M. Search for Related Content PubMed PubMed Citation Articles by Grunfeld, J. P. Articles by Worcel, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Steroids Hazardous Substances DB PROGESTERONE RU-486 SODIUM SPIRONOLACTONE

Hypertension, Vol 7, 292-299, Copyright © 1985 by American Heart Association

ARTICLES

Effects of antiglucocorticoids on glucocorticoid hypertension in the rat

JP Grunfeld, L Eloy, AM Moura, D Ganeval, B Ramos-Frendo and M Worcel

The early phase of hypertension induced in rats by a glucocorticoid agonist RU 26988 was studied. Systolic blood pressure increased by 35 mm Hg. Water and sodium urinary excretion increased transiently, and plasma volume decreased. Total and ouabain-sensitive sodium efflux, as well as rubidium efflux, were enhanced by glucocorticoid administration. Low salt intake did not prevent hypertension. Pretreatment with RU 38486, a steroid with antiglucocorticoid properties, largely prevented the rise in blood pressure (+10 mm Hg) and suppressed transient natriuresis and the decrease in plasma volume. Changes in total and ouabain-sensitive sodium efflux were completely prevented, whereas changes in rubidium efflux were only partly reversed. Similarly, administration of progesterone, a steroid with antiglucocorticoid effects, prevented glucocorticoid hypertension (+11 mm Hg) and vascular ionic changes. In contrast administration of RU 28318, an antimineralocorticoid agent, was without effect on glucocorticoid hypertension (+38 mm Hg). Progesterone or RU 38486 administered after glucocorticoid also decreased blood pressure. Present data indicate that glucocorticoid hypertension may be prevented or reversed in its early phase by steroid drugs with antiglucocorticoid properties. These drugs also appeared to prevent the sodium and rubidium flux abnormalities induced by glucocorticoid. We suggest that activation of the vascular glucocorticoid receptors may be involved in the pathophysiology of glucocorticoid hypertension.

This article has been cited by other articles:

				W. Drescher, D. Varoga, T. R. Liebs, J. Lohse, T. Herdegen, J. Hassenpflug, and T. Pufe Femoral Artery Constriction by Norepinephrine Is Enhanced by Methylprednisolone in a Rat Model J. Bone Joint Surg. Am., November 1, 2006; 88(suppl_3): 162 - 166. [Abstract] [Full Text] [PDF]

				S. S. Shank and D. A. Scheuer Glucocorticoids reduce responses to AMPA receptor activation and blockade in nucleus tractus solitarius Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1751 - H1761. [Abstract] [Full Text] [PDF]

				D. A. Scheuer and S. W. Mifflin Glucocorticoids modulate baroreflex control of renal sympathetic nerve activity Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2001; 280(5): R1440 - R1449. [Abstract] [Full Text] [PDF]

				K. M. Kayes-Wandover and P. C. White Steroidogenic Enzyme Gene Expression in the Human Heart J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2519 - 2525. [Abstract] [Full Text]

				R. M. Sapolsky, L. M. Romero, and A. U. Munck How Do Glucocorticoids Influence Stress Responses? Integrating Permissive, Suppressive, Stimulatory, and Preparative Actions Endocr. Rev., February 1, 2000; 21(1): 55 - 89. [Abstract] [Full Text]

				L. Michea, V. Valenzuela, I. Bravo, A. Schuster, and E. T. Marusic Adrenal-dependent modulation of the catalytic subunit isoforms of the Na+-K+-ATPase in aorta Am J Physiol Endocrinol Metab, December 1, 1998; 275(6): E1072 - E1081. [Abstract] [Full Text] [PDF]

				J. C. Clapham and N. C. Turner Effects of the Glucocorticoid II Receptor Antagonist Mifepristone on Hypertension in the Obese Zucker Rat J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1503 - 1508. [Abstract] [Full Text]